Sell in May and Go Away-Starting With These 3 Stocks DexCom (NASDAQ:DXCM) used its 2026 Investor Day to outline a long-range plan centered on new product launches, broader insurance coverage for ...

San Diego device maker Dexcom has received the first FDA clearance for a continuous glucose monitor that doesn’t require a doctor’s prescription. The U.S. Food and Drug Administration cleared Dexcom’s ...

March 24--Shares of DexCom gained more than 8 percent Friday after Medicare issued a favorable ruling for reimbursing use of continuous glucose monitors, made by the San Diego-based company. DexCom ...

DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring for people with diabetes, today announced a significant advancement in access to its products for those treating ...

DexCom Inc. DXCM recently announced that its G7 Continuous Glucose Monitoring (CGM) System will be added to the Régie de l'assurance maladie du Québec (RAMQ) Public Prescription Drug Insurance Plan.